Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company is also developing DFN-529, a phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway inhibitor. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
IPO Year:
Exchange: NASDAQ
Website: diffusionpharma.com
| Date | Price Target | Rating | Analyst |
|---|
8-K - CervoMed Inc. (0001053691) (Filer)
8-K - CervoMed Inc. (0001053691) (Filer)
8-K - CervoMed Inc. (0001053691) (Filer)
8-K - CervoMed Inc. (0001053691) (Filer)
8-K - CervoMed Inc. (0001053691) (Filer)
8-K - CervoMed Inc. (0001053691) (Filer)
8-K - CervoMed Inc. (0001053691) (Filer)
10-Q - CervoMed Inc. (0001053691) (Filer)
8-K - CervoMed Inc. (0001053691) (Filer)
8-K - CervoMed Inc. (0001053691) (Filer)
This live feed shows all institutional transactions in real time.
SC 13G/A - CervoMed Inc. (0001053691) (Subject)
SC 13D - CervoMed Inc. (0001053691) (Subject)
SC 13G - CervoMed Inc. (0001053691) (Subject)
SC 13D - CervoMed Inc. (0001053691) (Subject)
SC 13D - CervoMed Inc. (0001053691) (Subject)
Live Leadership Updates
CHARLOTTESVILLE, Va., May 18, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced that Raven Jaeger, M.S., has joined the Company as its Chief Regulatory Officer effective immediately. Ms. Jaeger will be responsible for development and implementation of regulatory and related strategies to support the development and commercialization of Diffusion's product development candidates, including the Company's lead candidate, trans sodium crocetinate (TSC), which is planned for development as an adju
Completed Dosing in Altitude Trial; Topline Data Expected in June 2022Blinded, Interim Data to be Presented at UHMS Annual Scientific Meeting in May 2022Ended Quarter with $32.6 Million in Cash, Cash Equivalents and Marketable SecuritiesRegained Compliance with Nasdaq Bid Price Rule CHARLOTTESVILLE, Va., May 12, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced financial results for the quarter ended March 31, 2022, and provided a business update. Business Updates Completed Dosin
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - CervoMed Inc. (0001053691) (Issuer)
3 - CervoMed Inc. (0001053691) (Issuer)
4 - CervoMed Inc. (0001053691) (Issuer)
4 - CervoMed Inc. (0001053691) (Issuer)
4 - CervoMed Inc. (0001053691) (Issuer)
4 - CervoMed Inc. (0001053691) (Issuer)
4 - CervoMed Inc. (0001053691) (Issuer)
4 - CervoMed Inc. (0001053691) (Issuer)
4 - CervoMed Inc. (0001053691) (Issuer)
4 - CervoMed Inc. (0001053691) (Issuer)
Fastest customizable press release news feed in the world
Approximately 71% of Stockholders Voted in Favor of the TransactionDiffusion Announces 1-for-1.5 Reverse Stock SplitMerger on Track to Close on August 16, 2023 CHARLOTTESVILLE, Va., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) today announced that its stockholders have voted to approve all proposals at a special meeting of stockholders held earlier today, including the issuance of Diffusion Common Stock in the pending merger with EIP Pharma Inc. ("EIP"), and a reverse stock split of outstanding Diffusion Common Stock (the "Reverse Split"). Dr. Robert Cobuzzi, President and Chief Executive Officer of Diffusion, said, "We are pleased with the outcome of to
Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging Combined company expected to have a cash runway through Phase 2b clinical data and to the end of 2024 Transaction has unanimous support of both EIP Pharma and Diffusion Boards of Directors BOSTON and CHARLOTTESVILLE, Va., March 30, 2023 (GLOBE NEWSWIRE) -- EIP Pharma Inc. (EIP Pharma), a privately held clinical-stage company focused on developing treatments for neurodegenerative diseases, and Diffusion Pharmaceuticals Inc. (D
LifeSci Special Opportunities Master Fund Announces Support for Diffusion's Ongoing, Board-led Strategic Review Process and for Diffusion's Nominees at 2022 Annual Meeting New Director to be Appointed to Diffusion Board if Strategic Transaction Not Completed by mid-2023 CHARLOTTESVILLE, Va., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that may enhance the body's ability to deliver oxygen to areas where it is needed most, today announced that it has entered into a settlement agreement with LifeSci Special Opportunities Master Fund Ltd., affiliated entities and cert
Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review processDiffusion received bids from more than 15 companies participating in review processLifeSci invited to participate in review process on same terms as all other bidders following submission of client's unsolicited offer, but LifeSci instead chose to launch a proxy contest against our highly qualified boardLifeSci's track record demonstrates a highly troubling pattern of self-dealing and stockholder value destruction, including more than $1.3 billion of stockholder losses in recent SPAC transactionsDiffusion's board and management are fully committed to maxi
Announced Thorough Evaluation of a Range of Potential Strategic OpportunitiesContinued GBM Study Start-up ActivitiesEnded Quarter with $25.9 million in Cash, Cash Equivalents and Marketable Securities CHARLOTTESVILLE, Va., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that may enhance the body's ability to deliver oxygen to areas where it is needed most, today announced financial results for the quarter ended September 30, 2022, and provided a business update. "As previously announced, we formalized our efforts to identify and evaluate strategic opportunities during the
Diffusion in Active Bidding Stage and Encouraged by Response to the Strategic Review Process Diffusion Board of Directors Rejects Woefully Inadequate, Unsolicited Offer for the Company by client of Investment Bank LifeSci Capital LifeSci-affiliated Fund Commences Proxy Contest for Control of the Diffusion Board Following Rejection of Client's Offer Company Believes LifeSci Proxy Campaign is Attempt to Circumvent Strategic Review Process Date of Diffusion's 2022 Annual Meeting of Stockholders Set for December 30, 2022 CHARLOTTESVILLE, Va., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developin
CHARLOTTESVILLE, Va., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that may enhance the body's ability to deliver oxygen to areas where it is needed most, today announced that its Board of Directors (the "Board") has authorized a thorough review and evaluation of a range of potential strategic opportunities in the interest of enhancing stockholder value including transactional opportunities to better leverage the potential of trans sodium crocetinate ("TSC") and the Company's other assets. As part of the Company's previously disclosed, ongoing efforts to identify ac
• Aligned with FDA on Design of Phase 2 GBM Trial of TSC; Initiation Expected by End of 2022• Reported Positive Effects in TSC Altitude Trial• Ended Quarter with $28.5 million in Cash, Cash Equivalents and Marketable Securities• Expected Cash Runway into First Quarter of 2024 CHARLOTTESVILLE, Va., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that may enhance the body's ability to deliver oxygen to areas where it is needed most, today announced financial results for the quarter ended June 30, 2022, and provided a business update. Development Updates Aligned w
Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate ("TSC") in newly diagnosed glioblastoma multiforme ("GBM") patientsCompany to evaluate effects of TSC on tumor oxygenation using an innovative positron emission tomography ("PET") hypoxia imaging methodology with data expected within one year of study initiationDiffusion previously obtained Orphan Drug Designation for use of TSC in conjunction with radiotherapy for the treatment of GBM CHARLOTTESVILLE, Va., July 26, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing nov
Positive effects on oxygenation observed with the 2.5 mg/kg dose at the end of the exercise intervalPositive effects on post-exercise recovery based when comparing measurements 10 min post-exercise to measurements at the end of the exercise intervalTSC was safe and well-tolerated by all subjects with no serious adverse events reported CHARLOTTESVILLE, Va., June 23, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced positive effects from its second Oxygenation Trial, the Altitude Trial.